Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions
- 17 Oct 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 19 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.